



Through more than 40,000 patents on DNA molecules, companies have essentially claimed the entire human genome for profit, report researchers who analyzed the patents on human DNA. The researchers, from Weill Cornell Medical College and the University of Medicine & Dentistry of New Jersey (UMDNJ) say their study raises an alarm about the loss of individual “genomic liberty.”

The scientists examined two types of patented DNA sequences: long and short fragments. They discovered that 41% of the human genome is covered by longer DNA patents that often cover whole genes. They also found that, because many genes share similar sequences within their genetic structure, if all of the “short sequence” patents were allowed in aggregate, they could account for 100% of the genome. Furthermore, the authors found that short sequences from patents also cover virtually the entire genome, even outside of genes.

“If these patents are enforced, our genomic liberty is lost,” says the study’s lead author, Christopher E. Mason, Ph.D., an assistant professor of physiology and biophysics and computational genomics in computational biomedicine at the Institute for Computational Biomedicine at Weill Cornell. “Just as we enter the era of personalized medicine, we are ironically living in the most restrictive age of genomics. You have to ask, how is it possible that my doctor cannot look at my DNA without being concerned about patent infringement?”

The U.S. Supreme Court will review genomic patent rights in an upcoming hearing on April 15. At issue is the right of Myriad Genetics to claim patents not only on two key breast and ovarian cancer genes—BRCA1 and BRCA2—but also on any small sequence of code within BRCA1, including a striking patent for only 15 nucleotides.

In its study, the research team matched small sequences within BRCA1 to other genes and found that just this one firm’s patents also covered at least 689 other human genes—most of which have nothing to do with breast or ovarian cancer; rather, its patents cover 19 other cancers as well as genes involved in brain development and heart functioning.

“This means if the Supreme Court upholds the current scope of the patents, no physician or researcher can study the DNA of these genes from their patients, and no diagnostic test or drug can be developed based on any of these genes without infringing a patent,” says Dr. Mason.

He undertook the study because he realized that his research into brain and cancer disorders inevitably involved studying genes that were protected by patents.

Under U.S. patent law, genes can be patented by those researchers, either at companies or institutions, who are first to find a gene that promises a useful application, such as for a diagnostic test. For example, the patents received by a company in the 1990s on BRCA1 and BRCA2 enables it to offer a diagnostic test to women who may have, or may be at risk for, breast or ovarian cancer due to mutations in one or both of these genes. Women and their doctors have no choice but to use the services of the patents’ owner, which costs $3,000 per test, “whereas any of the hundreds of clinical laboratories around the country could perform such a test for possibly much less,” says Dr. Mason.

The impact on these patents is equally onerous on research, Dr. Mason adds. “Almost every day, I come across a gene that is patented—a situation that is common for every geneticist in every lab,” says Dr. Mason.

He and his research partner Jeffrey Rosenfeld, Ph.D., an assistant professor of medicine at UMDNJ and a member of the High Performance and Research Computing Group, sought to determine how many other genes may be impacted by gene patents, as well as the overall landscape of intellectual property on the human genome.

To conduct the study, Drs. Mason and Rosenfeld examined the structure of the human genome in the context of short and long fragments of DNA. They used matches to known genes that were confirmed to be present in patent claims, ranging from as few as 15 nucleotides to the full length of all patented DNA fragments.

Before examining the patented sequences, the researchers first calculated how many genes had common segments of 15 nucleotide (15mer), and found that every gene in the human genome matched at least one other gene in this respect, ranging from as few as five matches 15mer to as many as 7,688 gene matches. They also discovered that 99.999% of 15mers in the human genome are repeated at least twice.

“This demonstrates that short patent sequences are extremely nonspecific and that a 15mer claim from one gene will always cross-match and patent a portion of another gene as well,” says Dr. Mason. “This means it is actually impossible to have a 15mer patent for just one gene.”

Next, researchers examined the total sequence space in human genes covered by 15mers in current patent claims. They found 58 patents whose claims covered at least 10% of all bases of all human genes. The broadest patent claimed sequences that matched 91.5% of human genes. Then, when they took existing gene patents and matched patented 15mers to known genes, they discovered that 100% of known genes are patented.

“There is a real controversy regarding gene ownership due to the overlap of many competing patent claims. It is unclear who really owns the rights to any gene,” says Dr. Rosenfeld. “While the Supreme Court is hearing one case concerning just the BRCA1 patent, there are also many other patents whose claims would cover those same genes. Do we need to go through every gene to look at who made the first claim to that gene, even if only one small part? If we resort to this rule, then the first patents to be granted for any DNA will have a vast claim over portions of the human genome.”

A further issue of concern is that patents on DNA can readily cross species boundaries. A company can have a patent that they received for cow breeding and have that patent cover a large percentage of human genes. Indeed, the researchers found that one company owns the rights to 84% of all human genes for a patent they received for cow breeding. “It seems silly that a patent designed to study cow genetics also claims the majority of human genes,” says Dr. Rosenfeld.

The researchers also examined the impact of longer claimed DNA sequences from existing gene patents, which ranged from a few dozen bases up to thousands of bases of DNA, and found that these long, claimed sequences matched 41% (9,361) of human genes. Their analysis concluded that almost all clinically relevant genes have already been patented, especially for short sequence patents, showing all human genes are patented many times over.

“This is, so to speak, patently ridiculous,” adds Dr. Mason. “If patent claims that use these small DNA sequences are upheld, it could potentially create a situation where a piece of every gene in the human genome is patented by a phalanx of competing patents.”

In their discussion, the researchers argue that the U.S. Supreme Court now has a chance to shape the balance between the medical good versus inventor protection, adding that, in their opinion, the court should limit the patenting of existing nucleotide sequences, due to their broad scope and nonspecificity in the human genome.

“I believe that individuals have an innate right to their own genome, or to allow their doctor to look at that genome, just like the lungs or kidneys,” Dr. Mason says. “Failure to resolve these ambiguities perpetuates a direct threat to genomic liberty, or the right to one’s own DNA.”

Their study was published March 25 in Genome Medicine in an article titled “Pervasive sequence patents cover the entire human genome”.



























